Seizures in dialysis patients treated with recombinant erythropoietin. Review of the literature and guidelines for prevention.
Anemia is one of the major limitations to rehabilitation in patients with end-stage renal disease (ESRD). The efficacy of recombinant human erythropoietin (rHuEPO) in the treatment of renal anemia is well established. Nevertheless, rHuEPO therapy has been associated with serious untoward effects. There appears to be an increased risk of hypertension, not infrequently accompanied by hypertensive encephalopathy and seizures. The mechanism of hypertension remains uncertain. It is associated with an increase in blood viscosity, a reversal of hypoxic vasodilatation, and possibly, a direct pressor effect of the hormone. Seizures, otherwise, may be the result of cerebral hypoperfusion and, finally, of a focal cerebral edema. The guidelines for rHuEPO treatment and prevention of associated convulsions are outlined. The possible convulsive risk induced by this treatment, even at low doses, particularly in patients with a previous history of seizures, is stressed.
Beccari
M
M
Department of Nephrology and Dialysis, Ospedale Fatebenefratelli e Oftalmico, Milano, Italy.
D000740:Anemia / Q000209:etiology / Q000628:therapy; D004921:Erythropoietin / Q000009:adverse effects*; D006801:Humans; D006973:Hypertension / Q000209:etiology / Q000503:physiopathology; D011994:Recombinant Proteins / Q000009:adverse effects; D006435:Renal Dialysis / Q000009:adverse effects; D012640:Seizures / Q000209:etiology* / Q000503:physiopathology
D011994:Recombinant Proteins; D004921:Erythropoietin